Test results presented have implications for patients if they require emergency surgery. Last month, the FDA approved idarucizumab (marketed as Praxbind) as an agent that specifically reverses the ...

We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant effect of dabigatran in patients who had ...

Ingelheim, Germany., Today, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending European approval of ...

TORONTO, Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the anticoagulant effect of dabigatran (Pradaxa ® ...

The data were submitted to the FDA following idarucizumab’s accelerated approval last year, which is granted to therapies that address an unmet medical need. Interim data from a phase 3 study confirm ...

(HealthDay News) — Idarucizumab can reverse the anticoagulant effect of dabigatran in emergency situations, according to a study published in the New England Journal of Medicine. The research was ...

Ingelheim, Germany, 26. November 2015 – The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran ...

Idarucizumab (Praxbind, Boehringer Ingelheim) reversed the anticoagulant effect of dabigatran (Pradaxa, Boehringer Ingelheim) in more than 98% of patients with life-threatening bleeding or who were ...

Idarucizumab is the first agent to be licensed in the UK that reverses the anticoagulant effect of a non‑vitamin K antagonist oral anticoagulant (NOAC). Its action is specific against the NOAC ...

BERLIN — Using the monoclonal antibody reversal agent idarucizumab (Praxbind, Boehringer Ingelheim), researchers have shown rapid, complete, and sustained reversal of dabigatran etexilate (Pradaxa, ...